Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1035–1039. doi: 10.1038/bjc.1994.444

5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol.

G Boccuzzi 1, E Brignardello 1, M Di Monaco 1, V Gatto 1, L Leonardi 1, A Pizzini 1, M Gallo 1
PMCID: PMC2033679  PMID: 7981051

Abstract

Adrenal androgens show a dual and apparently opposite effect on the growth of oestrogen-responsive breast cancer: they stimulate growth on their own, but counteract the growth-stimulatory effect of oestrogens. Focusing on the inhibitory action we have studied the effects of 5-en-androstene-3 beta,17 beta-diol (ADIOL) on the growth of oestrogen-responsive MCF-7 breast cancer cells in the presence of oestrogens (oestradiol and diethylstilboestrol), antiestrogens (tamoxifen) and antiandrogens (hydroxyflutamide). The inhibition of oestrogen-stimulated growth, attained with nanomolar concentrations of ADIOL, was not modified by increasing concentrations of diethylstilboestrol up to 100 nM. This inhibition was counteracted by antiandrogens, which were unable to block the ADIOL stimulatory effect in steroid-free medium. On the other hand, in the presence of tamoxifen ADIOL showed an additive antiproliferative activity also in steroid-free medium, rather than the usual stimulatory effect. These results suggest that ADIOL stimulates breast cancer cell growth via oestrogen receptors, but inhibits oestrogen-stimulated growth via androgen receptors.

Full text

PDF
1035

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams J. B., Archibald L., Seymour-Munn K. Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor. Cancer Res. 1980 Oct;40(10):3815–3820. [PubMed] [Google Scholar]
  2. Adams J., Garcia M., Rochefort H. Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res. 1981 Nov;41(11 Pt 1):4720–4726. [PubMed] [Google Scholar]
  3. Boccuzzi G., Aragno M., Brignardello E., Tamagno E., Conti G., Di Monaco M., Racca S., Danni O., Di Carlo F. Opposite effects of dehydroepiandrosterone on the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Anticancer Res. 1992 Sep-Oct;12(5):1479–1483. [PubMed] [Google Scholar]
  4. Boccuzzi G., Brignardello E., di Monaco M., Forte C., Leonardi L., Pizzini A. Influence of dehydroepiandrosterone and 5-en-androstene-3 beta, 17 beta-diol on the growth of MCF-7 human breast cancer cells induced by 17 beta-estradiol. Anticancer Res. 1992 May-Jun;12(3):799–803. [PubMed] [Google Scholar]
  5. Brogden R. N., Chrisp P. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging. 1991 Mar;1(2):104–115. doi: 10.2165/00002512-199101020-00003. [DOI] [PubMed] [Google Scholar]
  6. Bulbrook R. D., Hayward J. L., Spicer C. C. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971 Aug 21;2(7721):395–398. doi: 10.1016/s0140-6736(71)90113-9. [DOI] [PubMed] [Google Scholar]
  7. Chouvet C., Vicard E., Frappart L., Falette N., Lefebvre M. F., Saez S. Growth inhibitory effect of 4-hydroxy-tamoxifen on the BT-20 mammary cancer cell line. J Steroid Biochem. 1988 Oct;31(4B):655–663. doi: 10.1016/0022-4731(88)90015-5. [DOI] [PubMed] [Google Scholar]
  8. Demisch K., Magnet W., Neubauer M., Schöffling K. Studies about unconjugated androstenediol in human peripheral plasma. J Clin Endocrinol Metab. 1973 Jul;37(1):129–134. doi: 10.1210/jcem-37-1-129. [DOI] [PubMed] [Google Scholar]
  9. Garcia M., Rochefort H. Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Cancer Res. 1978 Nov;38(11 Pt 1):3922–3929. [PubMed] [Google Scholar]
  10. Hackenberg R., Turgetto I., Filmer A., Schulz K. D. Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells. J Steroid Biochem Mol Biol. 1993 Nov;46(5):597–603. doi: 10.1016/0960-0760(93)90187-2. [DOI] [PubMed] [Google Scholar]
  11. Helzlsouer K. J., Gordon G. B., Alberg A. J., Bush T. L., Comstock G. W. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res. 1992 Jan 1;52(1):1–4. [PubMed] [Google Scholar]
  12. Huynh H. T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 1993 Apr 15;53(8):1727–1730. [PubMed] [Google Scholar]
  13. Ingle J. N., Twito D. I., Schaid D. J., Cullinan S. A., Krook J. E., Mailliard J. A., Tschetter L. K., Long H. J., Gerstner J. G., Windschitl H. E. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991 Feb 15;67(4):886–891. doi: 10.1002/1097-0142(19910215)67:4<886::aid-cncr2820670405>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  14. Kreitmann B., Bayard F. Androgen interaction with the oestrogen receptor in human tissues. J Steroid Biochem. 1979 Nov-Dec;11(5-6):1589–1595. doi: 10.1016/0022-4731(79)90354-6. [DOI] [PubMed] [Google Scholar]
  15. MacIndoe J. H., Etre L. A. An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab. 1981 Oct;53(4):836–842. doi: 10.1210/jcem-53-4-836. [DOI] [PubMed] [Google Scholar]
  16. Nahoul K., Bournique B., Adeline J., Scholler R. Radioimmunoassay of 5-androstene-3 beta,17 beta-diol in plasma and in breast cyst fluid. J Steroid Biochem. 1986 Apr;24(4):835–842. doi: 10.1016/0022-4731(86)90444-9. [DOI] [PubMed] [Google Scholar]
  17. Najid A., Habrioux G. Biological effects of adrenal androgens on MCF-7 and BT-20 human breast cancer cells. Oncology. 1990;47(3):269–274. doi: 10.1159/000226830. [DOI] [PubMed] [Google Scholar]
  18. Neri R., Florance K., Koziol P., Van Cleave S. A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide). Endocrinology. 1972 Aug;91(2):427–437. doi: 10.1210/endo-91-2-427. [DOI] [PubMed] [Google Scholar]
  19. Nicholson R. I., Davies P., Griffiths K. Interaction of androgens with oestradiol-17beta receptor proteins in DMBA-induced mammary tumours--a possible oncolytic mechanism. Eur J Cancer. 1978 Apr;14(4):439–445. doi: 10.1016/0014-2964(78)90216-5. [DOI] [PubMed] [Google Scholar]
  20. Poortman J., Prenen J. A., Schwarz F., Thijssen J. H. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue. J Clin Endocrinol Metab. 1975 Mar;40(3):373–379. doi: 10.1210/jcem-40-3-373. [DOI] [PubMed] [Google Scholar]
  21. Poulin R., Baker D., Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat. 1988 Oct;12(2):213–225. doi: 10.1007/BF01805942. [DOI] [PubMed] [Google Scholar]
  22. Poulin R., Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. 1986 Oct;46(10):4933–4937. [PubMed] [Google Scholar]
  23. Poulin R., Simard J., Labrie C., Petitclerc L., Dumont M., Lagace L., Labrie F. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology. 1989 Jul;125(1):392–399. doi: 10.1210/endo-125-1-392. [DOI] [PubMed] [Google Scholar]
  24. Rochefort H., Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther. 1983;23(2):193–216. doi: 10.1016/0163-7258(83)90013-x. [DOI] [PubMed] [Google Scholar]
  25. Rosenfield R. L., Otto P. Androstenediol levels in human peripheral plasma. J Clin Endocrinol Metab. 1972 Dec;35(6):818–822. doi: 10.1210/jcem-35-6-818. [DOI] [PubMed] [Google Scholar]
  26. Simard J., Luthy I., Guay J., Bélanger A., Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986 Mar;44(3):261–270. doi: 10.1016/0303-7207(86)90132-2. [DOI] [PubMed] [Google Scholar]
  27. Thijssen J. H., Poortman J., Schwarz F. Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens. J Steroid Biochem. 1975 May;6(5):729–734. doi: 10.1016/0022-4731(75)90060-6. [DOI] [PubMed] [Google Scholar]
  28. Wang D. Y., Bulbrook R. D., Hayward J. L. Urinary and plasma androgens and their relation to familial risk of breast cancer. Eur J Cancer. 1975 Dec;11(12):873–877. doi: 10.1016/0014-2964(75)90087-0. [DOI] [PubMed] [Google Scholar]
  29. Zava D. T., McGuire W. L. Human breast cancer: androgen action mediated by estrogen receptor. Science. 1978 Feb 17;199(4330):787–788. doi: 10.1126/science.622569. [DOI] [PubMed] [Google Scholar]
  30. Zumoff B., Levin J., Rosenfeld R. S., Markham M., Strain G. W., Fukushima D. K. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res. 1981 Sep;41(9 Pt 1):3360–3363. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES